Denosumab
Approved, for something elseMeasured in people, not heightBy injectionAntibodyAlso Prolia, Xgeva
An injected antibody that removes the signal bone-dissolving cells need in order to exist. It treats thinning bones in adults, and under a second brand name, bone tumours.
Human IgG2 monoclonal antibody to RANKL. It keeps RANKL off RANK, so osteoclasts do not form, function or survive. Approved in two presentations. Prolia treats postmenopausal osteoporosis at high fracture risk, men with osteoporosis and glucocorticoid-induced osteoporosis, and increases bone mass under androgen deprivation therapy for prostate cancer or adjuvant aromatase inhibitor therapy for breast cancer — an adult in every indication. Xgeva, the oncology presentation, covers giant cell tumour of bone, and skeletal events in myeloma and in bone metastases from solid tumours.
Risks. It carries the strongest kind of label warning there is, for dangerously low blood calcium in people with advanced kidney disease, including those on dialysis. In children the label warns that long bone growth may be impaired and teeth held back from coming through, and the trials in children were stopped early for dangerously high blood calcium that put some of them in hospital.
On this page
- At the growth plate, members only
- Risks and side effects, members only
The rest of this page is for members
What has been measured, in whom, with every source, and what it does to the rest of you. And every article in the library.
Join for $11.99Lifetime · 3 of 10 founding spots left
Tax is added at checkout (VAT/GST where it applies).
Renews every month at the current price plus tax until you cancel. Cancel from your account before the next monthly charge to stop it.
Card purchases are sold and charged by Link (Stripe) under Link's terms and refund policy.
Already a member? Sign in
Educational content, not medical advice. Nothing here is a recommendation to take or stop taking anything — talk to a doctor about your own situation.